The front page of AI-driven biology
Friday, October 23, 2026Fri, Oct 23
Updated 12:02 PM PT
Bristol Myers Squibb and SystImmune reported that their bispecific antibody-drug conjugate, BL-B01D1, significantly extended progression-free survival compared to chemotherapy in a Phase 3 breast cancer trial.
An analysis of 97 cancer drug indications approved in Europe between January 2022 and July 2026 found that only 31% provided high clinical benefit under European Society for Medical Oncology grading standards.
Private equity firm CVC Capital Partners and Belgian investment company GBL secured a 74.3% controlling stake in Italian specialty pharmaceutical maker Recordati after raising their buyout offer to €53 per share.
Genentech reported that sefaxersen, a monthly subcutaneous antisense oligonucleotide targeting complement factor B, reduced proteinuria by 43.1% compared with placebo at 37 weeks in patients with IgA nephropathy.
In two pivotal Phase 3 trials named REMODEL-1 and REMODEL-2, remibrutinib, an oral Bruton's tyrosine kinase (BTK) inhibitor, reduced the annualized relapse rate by 35.2% and 31.2% compared with Sanofi's approved pill Aubagio (teriflunomide).
Researchers at RCSI and The Institute of Cancer Research mapped multiomic and single-cell profiles across roughly 2,000 colorectal tumors using an AI tool named iPhenMap.
The funding follows two subsidiary exits, including Incyte's buyout of Vega Therapeutics for up to $2 billion and a $350 million initial public offering for Electra Therapeutics.
Deep Track Capital, ADAR1 Capital, and Andreessen Horowitz joined the private placement alongside other backers, extending the combined company's runway into 2028.
Bristol Myers Squibb reported that a multiple sclerosis patient died from septic pneumonia following treatment with zola-cel, its autologous CD19-directed CAR-T cell therapy.
Arcotatug tavatecan, an antibody-drug conjugate directed against claudin18.2, improved median overall survival to 10.2 months compared to 6.9 months for investigator-chosen chemotherapy in a 464-patient Phase 3 trial.
Bristol Myers Squibb led the Series E funding round, which values the artificial intelligence drug developer at approximately $3 billion.
Long-term follow-up data show that adding the CDK4/6 inhibitor Kisqali (ribociclib) to endocrine therapy reduced the risk of death by 19% after six years in women with high-risk, early-stage breast cancer.
Roche has secured exclusive global development and commercialization rights to an experimental lung cancer drug from Zymeworks under an agreement valued at up to $813 million.
Combining an experimental drug from Tango Therapeutics with Revolution Medicines' Rasonque yielded an 82% tumor response rate in advanced pancreatic cancer patients, the companies reported in Madrid.
A systematic benchmark compared 11 image-based, transcriptomic, and multimodal segmentation methods across 15 datasets from five spatial platforms and 12 tissue types.
Swapping softmax reparameterization for simplex-projected gradient descent prevents early loss of promising amino acids during backpropagation-based protein design.
Multiphysics agent-based simulations of bone scans show premature aging blunts how bone cells respond to mechanical load.
An automated feature extraction pipeline built on second harmonic generation microscopy uses 87 interpretable structural metrics to quantify heart tissue remodeling in nonischemic heart failure.
Researchers applied the sequence-to-function neural network AlphaGenome to predict the regulatory impacts of roughly 17 million human-specific single-nucleotide mutations across 305 tissues and cell types.
Polymathic AI researchers developed the Latent Interconnect Protocol to map internal representations from specialized biological models straight into the latent states of large language models.
QProtFuse dynamically fuses intermediate representations across multiple layers of a protein language model rather than relying solely on the final output layer, guiding retrieval-augmented generation.